CV 1153
Latest Information Update: 13 May 2011
At a glance
- Originator Maxim Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Caspase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Liver disorders; Multiple organ failure; Myocardial infarction; Septic shock; Stroke
Most Recent Events
- 13 May 2011 Discontinued - Preclinical for Liver disorders in USA (IV)
- 13 May 2011 Discontinued - Preclinical for Multiple organ failure in USA (IV)
- 13 May 2011 Discontinued - Preclinical for Myocardial infarction in USA (IV)